Legend Biotech highlights solid tumor advance and long-term multiple myeloma survival at ASCO 2026
Legend Biotech (NASDAQ:LEGN) presented first-in-human clinical data for its investigational solid tumor therapy alongside long-term tracking metrics for its commercially approved blood cancer asset at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
The dual presentations highlighted the company's early progress in expanding CAR-T pipelines into aggressive solid tumors while solidifying the durable survival benefit of its primary commercial franchise.
The global cell therapy developer released initial Phase 1 data evaluating LB2102, a proprietary, DLL3-targeted chimeric antigen receptor T-cell (CAR-T) therapy designed to treat patients suffering from relapsed or refractory small cell lung cancer (SCLC) or large-cell neuroendocrine carcinoma (LCNEC).
Concurrently, the company shared updated analyses from the ongoing CARTITUDE clinical trial program for CARVYKTI (ciltacabtagene autoleucel), its approved B-cell maturation antigen (BCMA)-targeted CAR-T therapy co-promoted with Johnson & Johnson for the treatment of multiple myeloma.
The open-label Phase 1 trial for LB2102 tracked clinical responses and safety parameters across heavily pretreated patient groups facing advanced neuroendocrine lung malignancies.
Across all evaluation groups and dosing levels, the investigational cell therapy demonstrated a baseline overall objective response rate (ORR) of 20% and a disease control rate (DCR) of 70%.
A clearer clinical signal emerged within cohorts assigned to receive the study's higher dosing concentrations.
In those select higher-dose subsets, the objective response rate expanded to 28.6%, while the corresponding disease control rate reached 78.6%.
Clinical investigators characterized the overall safety profile of the armored CAR-T platform as manageable.
Adverse event tracking showed no instances of dose-limiting toxicities or treatment-related patient fatalities, establishing a viable safety threshold for ongoing clinical development.
In addition to its early-stage solid tumor disclosures, Legend Biotech shared updated long-term data from the CARTITUDE clinical framework confirming the sustained therapeutic benefit of CARVYKTI in multiple myeloma.
The updated tracking datasets demonstrated an overall survival (OS) rate exceeding 85% at the 30-month milestone within a key pre-specified high-risk patient subgroup.
The updated hematological analyses also reinforced the long-term safety and tolerability profile of the commercialized cell infusion.
Specifically, monitoring logs highlighted a low overall incidence rate of 1.2% for immune effector cell-associated enterocolitis (IEC-enterocolitis), a key gastrointestinal complication tracked closely during late-stage cellular therapy monitoring.